GAOMA Therapeutics is a pharmaceutical company developing a unique portfolio of innovative lipids derivatives as drug candidates. With its proprietary compounds, GAOMA is committed to address unmet medical needs notably in neurological or inflammatory diseases.
GAOMA has a particular expertise in the fields of epilepsy and cognitive disorders, with the intent to explore the potential of its molecules in other indications too.
The company was founded in 2019, based on the research outcomes of the Translational and Integrative Group in Epilepsy Research (TIGER), which is part of the Lyon Neuroscience Research Center (CRNL). GAOMA Therapeutics is headquartered in the Lyon area, within the European Institute of Epilepsy (IDEE).